Mouse Anti-HIV-1 gp160 Recombinant Antibody (clone 1577 (735-752)) (CAT#: MRO-3822CQ)

Figure 1 Untreated, proteinase K-treated, or proteinase K- and NP40-treated microsomal fractions were analyzed by Western blotting using human antiserum 95-2 against Env or monoclonal antibody 1577 directed against the cytoplasmic domain of gp41.

The extracellular domain of gp41 is ubiquitinated.

Bültmann, A., Eberle, J., & Haas, J. (2000). Ubiquitination of the human immunodeficiency virus type 1 env glycoprotein. Journal of virology, 74(11), 5373-5376.

Figure 2 Inhibition of transcytosis of cell-free HIV-1 through a tight HEC-1 epithelial barrier by 13 monoclonal antibodies and polyclonal antibodies to gp160

The results are expressed as means ± standard deviation of the percentages of transcytosis inhibition obtained in four separate experiments.

Chomont, N., Hocini, H., Gody, J. C., Bouhlal, H., Becquart, P., Krief-Bouillet, C., ... & Bélec, L. (2008). Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology, 370(2), 246-254.

Figure 3 Capacity of antibodies to interfere with the fusion inhibitor T20.

In the presence of monoclonal antibodies with or without T20. The antibodies used are indicated above the panels.

Vincent, N., & Malvoisin, E. (2012). Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell–cell fusion assay. Immunobiology, 217(10), 943-950.